University of Louisville homepage
All experts
All experts

Rebecca Redman

Professor

School of Medicine

Orcid identifier0000-0002-0932-8868
  • Professor
    School of Medicine

SPONSORED PROJECTS

Clinical trials to improve treatment for patients with head and neck cancers and cancers of the gastrointestinal tract (colorectal, gastric, esophageal, liver, and pancreatic cancers)

SPONSORED PROJECTS

  • Showing page 1 out of 5
Showing page 1, sponsored projects 1 to 25 of 101
GRANT
AWD-00000505 | NRG-HN016: Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin: a Pragmatic Phase III Randomized Trial (CONCISE)
NRG Oncology Foundation Inc_NRGOF8 Jan 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
AWD-00000554 | CLS-628-0001: A Phase 1b Dose Escalation and Dose Expansion Study to Evaluate ABBV-CLS-628 as Adjuvant Therapy in Participants with Unresectable Stage III\/IVa Head and Neck Squamous Cell Carcinoma Post Non-Immunotherapy Curative Intent Therapy
IQVIA RDS Inc_IQVIA (SPN-000259)1 Jan 2026 - 31 Dec 2026
MORELEARN MORE
GRANT
250583 | MK-5909-003-0009 - A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Merck and Company Inc_MERCKCO6 Sep 2025 - 6 Aug 2030
MORELEARN MORE
GRANT
240400|Protocol NRG-GI008, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) (NCT 05174169)
NRG Oncology Foundation Inc_NRGOF1 Jan 2025
MORELEARN MORE
GRANT
250408|A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors
Merck and Company Inc_MERCKCO1 Jan 2025
MORELEARN MORE
GRANT
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics Inc_BTI1 Jan 2025
MORELEARN MORE
GRANT
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination with Checkpoint Inhibition in Participants with Advanced Solid and Hematologic Tumors
Catalyst Clinical Research_CCR1 Jan 2025
MORELEARN MORE
GRANT
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent and in Combination in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair
Worldwide Clinical Trials Inc_WCT1 Jan 2025
MORELEARN MORE
GRANT
A Phase 3 Open-Label, Randomized Study of PDS0101 Plus Pembrolizumab vs Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Naïve Subjects with Unresectable Recurrent and/or Metastatic (R/M) Human Papillomavirus 16 (HPV16)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC)
Worldwide Clinical Trials Inc_WCT1 Jan 2025
MORELEARN MORE
GRANT
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors
1 Jan 2025
MORELEARN MORE
GRANT
240377|ASND0038-A R, Ph 2, Ol Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 ?/?, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable
Syneos Health_SH5 Jan 2024
MORELEARN MORE
GRANT
240630|MK-1200 - Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
Merck and Company Inc_MERCKCO1 Jan 2024
MORELEARN MORE
GRANT
240698|EA23191 -A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
ECOG ACRIN Cancer Research Group_ECOG1 Jan 2024
MORELEARN MORE
GRANT
230172|LCCC 2047- MK-3475: A phase II trial of induction and maintenance pembrolizumab and olaparib in locally advanced head and neck squamous cell carcinoma (HNSCC)
Univ of North Carolina _UNC10 Apr 2023
MORELEARN MORE
GRANT
230883|SRF114-101 A Phase 1/2 Study of SRF114 in Patients with Advanced Solid Tumors: Phase I/II anti-CCR8 monoclonal antibody clinical trial in patients with Advanced Solid Tumors and Head and Neck Squamous Cell Carcinoma (HNSCC)
Precision for Medicine_PFM5 Apr 2023
MORELEARN MORE
GRANT
240845|MK-2870 -A Phase 3 Study to Evaluate MK-2870 in Advanced/Metastatic Gastroesophageal Adenocarcinoma
Merck and Company Inc_MERCKCO5 Jan 2023
MORELEARN MORE
GRANT
230171|STAR-221 -A R, OLl, MC Ph 3 Trial of Domvanalimab, Zimberelimab, & Chemotherapy Versus Nivolumab & Chemotherapy in Participants w Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal
Arcus Biosciences Inc_ARCUSBIO1 Jan 2023
MORELEARN MORE
GRANT
230358|MK-4464-001 A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
Merck and Company Inc_MERCKCO1 Jan 2023
MORELEARN MORE
GRANT
230359|VCN-01 - A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Orion Sante Sarl_OSS1 Jan 2023
MORELEARN MORE
GRANT
230369|ARC-20: A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy in participants with clear cell renal cell carcinoma and other solid tumors
ICON Clinical Research_ICON1 Jan 2023
MORELEARN MORE
GRANT
230430|NGM438 -A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals Inc_NGMB1 Jan 2023
MORELEARN MORE
GRANT
230525|BNT122-01 -A MS, OL, Phase II, R, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer pts who are ctDNA positive following resection
ICON Clinical Research_ICON1 Jan 2023
MORELEARN MORE
GRANT
240450|A022104 - The Janus Rectal Cancer Trial: A Randomized Phase Ii Trial Testing The Efficacy Of Triplet Versus Doublet Chemotherapy To Achieve Clinical Complete Response In Patients With Locally Advanced Rectal Cancer
Alliance for Clinical Trials in Onc_ACTO1 Jan 2023
MORELEARN MORE
GRANT
220671|HN009 -Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally HN009 -Advanced Squamous Cell Carcinoma of the Head
NRG Oncology Foundation Inc_NRGOF2 Nov 2022
MORELEARN MORE
GRANT
220672|HN008 - Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT, In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NRG Oncology Foundation Inc_NRGOF2 Nov 2022
MORELEARN MORE